Drug Approval | January 28, 2022
European Commission approves Merck’s KEYTRUDA as adjuvant therapy for RCC
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
KEYTRUDA is now approved as monotherapy for adults with Renal Cell Carcinoma (RCC)
The award was given as a result of NASSCOM's meticulous screening process, in which over 700 start-ups were shortlisted as the most promising companies of the year
Direct to consumer pharmacy and formation as pharmacy benefit manager further mission to drastically expand access to affordable pharmaceuticals
Evrysdi is approved in 70 countries and submitted in a further 31 with more than 4,500 patients treated to date
New role strengthens Quantori’s global leadership position in data science & digital IT
Studies show significant reduction in pain and improved quality of life for patients treated with spinal cord stimulation compared to medication management alone
The covid health center will be managed and administered by the district administration of Ballari
Merck is studying the Complete Response Letter and it is not related to the safety of gefapixant
Companies plan to commercialize breath-based detection of lung infection and transplant rejection
The collaboration with Sanofi signifies a considerable investment in the UK’s Life Sciences sector and, along with other future strategic partners, has the potential to increase the pipeline of potential treatment options for a wide range of common and other life-threatening diseases
Subscribe To Our Newsletter & Stay Updated
